European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News
Type: News Feed

Orphan designation: human IgG1 monoclonal antibody against JC polyomavirus, major capsid protein VP1 Treatment of progressive multifocal leukoencephalopathy, 22/06/2026 Positive

Submitted by Anonymous (not verified) on 24 August 2026 - 13:28

Orphan designation: human IgG1 monoclonal antibody against JC polyomavirus, major capsid protein VP1 Treatment of progressive multifocal leukoencephalopathy, 22/06/2026 Positive

Orphan designation: (S)-Quinuclidin-3-yl((R)-5-(3-chloro-4-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate ((1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)methanesulfonate Treatment of Gaucher disease, 22/06/2026 Positive

Submitted by Anonymous (not verified) on 24 August 2026 - 13:26

Orphan designation: (S)-Quinuclidin-3-yl((R)-5-(3-chloro-4-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate ((1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)methanesulfonate Treatment of Gaucher disease, 22/06/2026 Positive

Orphan designation: 3-(Aminocarbonyl)-1-(2,3,5-tri-O-acetyl-beta-D-ribofuranosyl)-pyridinium chloride (1:1) Treatment of ataxia telangiectasia, 22/06/2026 Positive

Submitted by Anonymous (not verified) on 24 August 2026 - 13:20

Orphan designation: 3-(Aminocarbonyl)-1-(2,3,5-tri-O-acetyl-beta-D-ribofuranosyl)-pyridinium chloride (1:1) Treatment of ataxia telangiectasia, 22/06/2026 Positive

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More